Cem Gabay, MD, professor of medicine at the University of Geneva, presented results of a study on the use of sarilumab on circulating biomarkers of bone and joint destruction in patients with rheumatoid arthritis who had shown an inadequate response to methotrexate.
By way of background, he stated that researchers know that synovial inflammation leads to bone damage. There is also a cascade of signaling events that contribute to this damage.
In addition, he said that more recently, different synovial phenotypes have shown different responses to biologic agents.
He briefly explained the study’s methodology, which included biomarkers measured using validated ELISAs; randomly selected subsets of patients receiving different amounts of a drug; and evaluating changes (modest differences in some biomarker levels) in patients classified as ACL responders and non-ACL responders at 6 months.
Among his findings were that sarilumab reduced disease activity and improved physical function—all superior to Methotrexate alone.
He presented baseline demographics and disease characteristics, noting that older patients were included. But the baseline characteristics were basically similar. Further, the baseline serum levels of most of the biomarkers were similar—even quite comparable—between treatment groups.
Some of these reductions could be seen as early as two weeks after just one injection, suggesting a subset of the biomarkers may be associated with a decrease in disease activity.
Specifically, sarilumab:
The study showed that patients using sarilumab showed a significantly higher magnitude of change in biomarkers of inflammation and bone or joint degradation—as compared to patients treated with methotrexate. Further, for some of these markers, the difference was observed as early as two weeks after treatment began.
A stronger way to put this was: sarilumab significantly reduced biomarkers of synovial inflammation and bone remodeling.
What this means, explained Gabay, was that clinicians learned which biomarkers to follow concerning the response of patients to this drug.
While he was not surprised at the results of using Sarilumab, he was surprised at the speed with which they were produced—that the medication worked as quickly as two weeks. The results he displayed for CRP were well known, he said, but for other markers of synovial inflammation, it was, he pointed out, a good surprise that the changes occurred so quickly.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More